US Patent

US12357697 — Pharmaceutical compositions comprising bupropion and cysteine

Method of Use · Assigned to Axsome Therapeutics Inc · Expires 2043-01-20 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions and dosage forms that combine bupropion and cysteine.

USPTO Abstract

This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3419`	—

Patent Metadata

Patent number: US12357697
Jurisdiction: US
Classification: Method of Use
Expires: 2043-01-20
Drug substance claim: No
Drug product claim: No
Assignee: Axsome Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.